KALARIS THERAPEUTICS INC (KLRS:NASDAQ)
$4.65 0.28 (6.4073%)
Analysed KALARIS THERAPEUTICS INC (KLRS:NASDAQ) News Sources
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
12-11-2025
yahoo.com
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
24-11-2025
yahoo.com
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully
27-11-2025
yahoo.com
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
17-12-2025
yahoo.com
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
17-12-2025
yahoo.com
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
28-01-2026
yahoo.com
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
17-03-2026
yahoo.com
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
12-05-2026
yahoo.com
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
14-05-2026
yahoo.com
Kalaris to Present at Clinical Trials at the Summit 2026
12-06-2026
yahoo.com
What is the current price of KALARIS THERAPEUTICS INC (KLRS:NASDAQ)?
The current price of KALARIS THERAPEUTICS INC (KLRS:NASDAQ) is $4.65.
KALARIS THERAPEUTICS INC (KLRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of KALARIS THERAPEUTICS INC (KLRS:NASDAQ) since the previous trading day is $0.28.
KALARIS THERAPEUTICS INC (KLRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of KALARIS THERAPEUTICS INC (KLRS:NASDAQ) since the previous trading day is 6.4073%.
What is the most recent average sentiment score for KALARIS THERAPEUTICS INC (KLRS:NASDAQ)?
The most recent average sentiment score for KALARIS THERAPEUTICS INC (KLRS:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for KALARIS THERAPEUTICS INC (KLRS:NASDAQ)?
The most recent sentiment for KALARIS THERAPEUTICS INC (KLRS:NASDAQ) is .
SEC-8K** Filing Available For KALARIS THERAPEUTICS INC (KLRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.